Jant Pharmacal Corporation is awarded contract from Vizient

Jan. 7, 2020

Jant Pharmacal Corporation has announced it has been awarded a contract with Vizient, Inc. for its complete line of rapid test kits. The contract takes effect February 1, 2020, and offers enhanced savings on the test kits for Vizient members.

The contract covers Jant’s full line of test kits, which is comprised of tests for cancer screening, drugs of abuse, infectious disease, pregnancy and urinalysis.

Vizient’s diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and nonacute health care providers and represents more than $100 billion in annual purchasing volume.

Visit Jant Pharmacal for more news